Prevalence of Rhabdomyosarcoma in the U.S. from 2017-2018: A SEER study

J Natl Med Assoc. 2023 Aug;115(4):403-404. doi: 10.1016/j.jnma.2023.06.001. Epub 2023 Jun 10.

Authors

Promise Ufomadu¹, Shangyi Fu², Danny Huynh³

Affiliations

¹ Baylor College of Medicine, School of Medicine, One Baylor Plaza,Houston, TX 77030, USA. Electronic address: Promise.Ufomadu@bcm.edu.
² Baylor College of Medicine, School of Medicine, One Baylor Plaza,Houston, TX 77030, USA; Baylor College of Medicine, Human Genome Sequencing Center, Houston, TX, USA.
³ Embedded Systems Engineering, Teal Systems, Houston, TX, USA.

PMID: 37308344
DOI: 10.1016/j.jnma.2023.06.001

No abstract available

Keywords: Cancer; Demographic contributors; Malignancy; Mesenchymal tumor; Myosarcoma; Neoplasia; Rhabdomyosarcoma; SEER.

Publication types

Letter

MeSH terms

Humans
Prevalence
Rhabdomyosarcoma* / epidemiology